- Home
- RLYB vs MREO Comparison
RLYB vs MREO Comparison
Compare RLYB & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLYB | MREO |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.6M | 52.5M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RLYB | MREO |
|---|---|---|
| Price | $8.25 | $0.33 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 89.8K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $858,000.00 | $500,000.00 |
| Revenue This Year | N/A | $6,000.20 |
| Revenue Next Year | N/A | $34.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 43.00 | N/A |
| 52 Week Low | $0.24 | $0.20 |
| 52 Week High | $11.49 | $2.94 |
Technical Indicators
Market Signals| Indicator | RLYB | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 51.44 | 40.25 |
| Support Level | $7.90 | $0.32 |
| Resistance Level | $9.25 | $0.42 |
| Average True Range (ATR) | 0.50 | 0.02 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 29.74 | 29.29 |
Price Performance
Historical ComparisonAbout RLYB Rallybio Corporation
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).